2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 104

Identification of Joints with Active Arthritis from Clinical Notes with High Fidelity using a Large Language Model
Abstract Number: 101

Identifying Intervention Targets to Reduce Emotional Distress and Improve Physical Activity in Juvenile Lupus and Dermatomyositis Patients: Longitudinal Analysis of Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Study Patient-Reported Resiliency Data
Abstract Number: 060

Impact of Social Determinants of Health on Outcomes in Pediatric Uveitis
Abstract Number: 061

Impacts of Social Drivers of Health on Outcomes for Patients with Pediatric Systemic Lupus Erythematosus
Abstract Number: 063

Improving Pediatric Lupus Patient Education: Patient and Provider Needs Assessment
Abstract Number: 142

Improving Recognition and Management of Glucocorticoid-Induced Adrenal Insufficiency in Pediatric Rheumatology Patients
Abstract Number: 114

Incidence of Inflammatory Arthritis Before and After Inflammatory Bowel Disease Diagnosis: A Population-Based Cohort Study
Abstract Number: 066

Incidence of Juvenile Idiopathic Arthritis in Chile: Estimates from a National Universal Access Program, 2010-2024
Abstract Number: 058

Increasing Reproductive Health Counseling and Screening in a Pediatric Rheumatology Clinic Using Quality Improvement Principles and Diverse Group of Stakeholders
Abstract Number: 077

Integrated Spatial Transcriptomics and Proteomics in Reveals Aberrant Lymphoid Networks in Pediatric Lupus Nephritis
Abstract Number: 073

Interleukin-6 and Interleukin-12 Stimulation Increases Fibroblast Migration in Localized Scleroderma and Healthy Control Primary Fibroblasts
Abstract Number: 098

Investigating S100 Proteins as Biomarkers for Pediatric Localized Scleroderma
Abstract Number: 056

Journey Maps of the Diagnostic Process: Insights from Caregivers of Patients with Juvenile Idiopathic Arthritis
Abstract Number: 110

Juvenile Idiopathic Inflammatory Myopathies and Macrophage Activation Syndrome: A Case Series
Abstract Number: 013

Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].